The U.S. Food and Drug Administration (FDA) has approved a new treatment for uncomplicated urinary tract infections (uUTI).

Orlynvah oral tablets are taken twice a day for five days and are intended for use in uUTIs caused by certain bacteria (Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis) in women who have limited oral treatment options.

It is not indicated for treatment of complicated urinary tract infections, where clinical trials did not show effectiveness.

Two clinical trials did show Orlynvah’s effectiveness with women who had amoxicillin/clavulanate-susceptible pathogens and with ciprofloxacin-resistant pathogens.

The most common side effects were diarrhea, nausea, vaginal yeast infection, headache, and vomiting. 

Approximately half of all women will have at least one uUTI in her lifetime.